Maxalt Lyo (Rizatriptan Benzoate)

Rizatriptan belongs to the triptan class and is used for the acute management of migraine attacks.

• Migraine (with or without aura): aborts an ongoing headache episode and reduces associated nausea and photophobia.
• Migraine‑related nausea: helps alleviate gastrointestinal discomfort that often accompanies attacks.
• Migraine‑induced photophobia: diminishes sensitivity to light during an acute episode.

• Rizatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation causes vasoconstriction of intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the migraine cascade and relieving pain.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Taste disturbance: a metallic or bitter taste in the mouth.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Dry mouth: reduced salivation leading to throat discomfort.
• Nausea: mild stomach upset.

Serious or Rare Side Effects

• Chest pain or tightness: may indicate cardiac involvement.
• Serotonin syndrome: agitation, hyperthermia, and muscle rigidity when combined with other serotonergic agents.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hypertension: sudden increase in blood pressure.
• Myocardial infarction: rare but life‑threatening heart attack.

Before prescribing Maxalt Lyo, clinicians should evaluate patient history and comorbid conditions.

• Cardiovascular disease: avoid in patients with coronary artery disease, uncontrolled hypertension, or history of stroke.
• Hemiplegic or basilar migraine: contraindicated due to increased vascular risk.
• Concomitant serotonergic drugs: monitor for serotonin syndrome.
• Liver or renal impairment: dose adjustment may be required.
• Store at room temperature: keep in the original package, protect from moisture and direct sunlight.

Rizatriptan can interact with several medication classes, requiring careful review.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension and serotonin syndrome.
• Ergot alkaloids: additive vasoconstrictive effects may precipitate coronary spasm.

Moderate Interactions (Monitor Closely)

• SSRIs or SNRIs: increase serotonin levels, monitor for serotonin syndrome.
• Antihypertensive agents: may enhance blood pressure‑lowering effects.
• CYP3A4 inhibitors: can raise rizatriptan plasma concentrations, adjust therapy as needed.